전이성 뇌종양(BM) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Brain Metastasis (BM) Emerging Therapy and TPP Insights

Thelansis's "Brain Metastasis (BM) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Brain Metastasis (BM) Overview

Brain metastasis is the most prevalent intracranial malignancy in adults, occurring when neoplastic cells from a primary tumor-overwhelmingly originating from the lung, breast, melanoma, or kidney-disseminate hematogenously, breach the blood-brain barrier, and colonize the central nervous system parenchyma. Clinically, patients present with debilitating symptoms driven by rapid mass effect and profound vasogenic peritumoral edema, classically including escalating headaches, new-onset seizures, and distinct focal neurological deficits. Definitive diagnosis mandates a contrast-enhanced magnetic resonance imaging (MRI) scan of the brain. Because the acute intracranial pressure is life-threatening, immediate supportive management universally requires the potent corticosteroid dexamethasone to rapidly reverse edema and stabilize neurological function. The definitive therapeutic paradigm is highly individualized and multidisciplinary; while maximal safe surgical resection is prioritized for large, accessible, or acutely symptomatic lesions, the cornerstone of local control relies on highly conformal stereotactic radiosurgery (SRS). Crucially, modern oncology heavily restricts the historical use of whole-brain radiation therapy (WBRT)-reserving it only for extensive disease and frequently employing hippocampal-avoidance techniques-to rigorously mitigate severe, irreversible neurocognitive toxicity. Furthermore, the modern systemic paradigm has been revolutionized by next-generation, CNS-penetrant targeted therapies (such as specialized tyrosine kinase inhibitors) and immune checkpoint blockade, which now provide a critical mechanism to simultaneously eradicate both intracranial and extracranial disease, profoundly extending survival and preserving quality of life.

Key Highlights

• Total BM cases are projected to increase from 299,337 in 2025 to 321,620 by 2035, indicating a growing disease burden.
• Rising incidence is driven by improved survival in primary cancers and better detection through advanced imaging.
• Significant clinical burden due to neurological complications and reduced quality of life.
• Treatment paradigm has shifted toward SRS and CNS-active systemic therapies, reducing reliance on WBRT.
• Persistent unmet need in patients with multiple lesions, resistance to therapy, and limited CNS drug penetration.

Market Overview

• The United States BM market is projected to slightly decline from $3.25M to $3.18M, indicating a relatively stable to marginally contracting market.
• Market dynamics are influenced by:
• Shift toward targeted and immunotherapy-based systemic treatments
• Reduced utilization of traditional radiation approaches (WBRT)
• Despite increasing patient numbers, market growth is constrained by treatment consolidation and evolving care pathways.
• Adoption of precision oncology and CNS-penetrant agents is reshaping treatment strategies.
• Future market trends will depend on innovative therapies improving intracranial response and survival outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Blue Earth Diagnostics
• GT Medical Technologies, Inc.
• Radiopharm Theranostics, Ltd
• Allist Pharmaceuticals, Inc.
• UNICANCER
• A2A Pharmaceuticals Inc.
• Medolution Ltd.
• NovoCure GmbH
• MedSIR
• Alpha Biopharma (Jiangsu) Co., Ltd.
• Duke Street Bio Ltd
• Reveal Pharmaceuticals Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)